Your Frozen Architecture May Have a Backdoor

Picture this: A validated electronic data capture system in a clinical trial gets breached. An attacker modifies efficacy endpoint data in the database. The change is discoverable: the audit trail shows altered records, timestamps don't match, and the investigation follows a clear path. IT remediates the access, the clinical data management team assesses impact, and the deviation is documented. Two domains, two workstreams, clear boundaries.

Now picture this: Your clinical drug development team has hundreds of millions of pathology samples flowing through an AI-assisted diagnostic classification model, with federated data inter-sharing between academic medical centers and community health systems. An attacker compromises one contributing institution's data pipeline: not the model itself, but the upstream image repository that feeds it. They introduce a small number of subtly mislabeled samples into the training or fine-tuning data: a fraction of early-stage malignancies labeled as benign, scattered across thousands of cases. The model doesn't break or flag errors. It recalibrates slightly, and its classification threshold for that tumor subtype drifts just enough to reduce sensitivity. The confidence scores still look normal. The validated golden-set rescoring might not catch it if the poisoned distribution is close enough to the natural edge cases the model already struggles with.

Now your clinical team is making go/no-go decisions on a compound's efficacy based on AI-assisted pathology reads that are ever so slightly undercounting responders. The signal-to-noise ratio in your trial shifts. Not dramatically; just enough that a borderline effective therapy looks ineffective, or an ineffective one looks borderline.

No one in IT sees a breach because the data pipeline technically functioned per specifications. No one in validation sees a failure because the model is performing within its accepted statistical thresholds. The compromise lives in the space between those two domains, and the patient safety consequence doesn't surface until someone asks why the Phase II results don't match the preclinical signal.

Stanford’s 2025 AI Index Report documented a 56.4% increase in AI-related security incidents in the previous year (2024-2025).

Right now, every drug development company adopting AI tools is asking their IT team about network security and their validation team about model performance. Nobody is asking the question that sits between those two domains: what does a validated AI system mean when the infrastructure it runs on can be compromised by a teenager with stolen credentials?

Historically, GxP validation and traditional IT security operated in two separate domains. 

Validation asks: “Is this system fit for its intended purpose? And what evidence proves it?”

IT asks: “Is the network protected? Are credentials managed? Are firewalls configured?”

For deterministic software, this separation worked. A network breach was an IT event. A validation failure was a quality event. Clear separation of duties.

Enter probabilistic technology. While versions of this existed before the GPT “era”, the advent of modern neural networks catalyzed a worldwide frenzy of excitement over artificial intelligence and its capabilities. With these advancements, natural drift and adversarial manipulation can, and often do, become indistinguishable. 

The playbook has shifted, and the rulebook must evolve to match it. An AI system’s validated state depends on the architecture it rests upon: model weights, training data, prompt templates, retrieval databases (RAG sources), API connections, cloud infrastructure.

Several types of surface exposure unique to probabilistic technology exist: 

• Data poisoning: Many researchers consider data poisoning as potentially the most vulnerable entry point. In a January 2026 study in the Journal of Medical Internet Research (Abtahi et al.), researchers analyzed multiple independent empirical studies and concluded that attack success depends on absolute sample count rather than poisoning rate. Only a fraction of compromised samples (hundreds out of millions) are needed to shift model behavior. The potential downstream consequences are severe: over or underestimating the efficacy of ineffective compounds, or modified pharmacovigilance data suppressing adverse event signals.

• Adversarial attacks: Adversarial attacks, or intentional perturbations, can potentially reconstruct proprietary structures, presenting a risk to substantial intellectual property (IP). Research has identified a tactic called “drift adversarial”, which are specific drift patterns designed to exploit weaknesses in drift detection methods (Hinder et al. 2024).

• Supply chain vulnerabilities: Each supply chain dependency presents an additional exposure channel. Open-source AI/ML tools, pre-trained frontier models and cloud-hosted APIs all present potential attack vectors. OWASP elevated "Model and Data Supply Chain Compromise" to the number one position on its AI Security Top 10 list for 2025. Data poisoning, such as via Retrieval Augmented Generation (RAG) during training, is another area of concern.

A breach of AI infrastructure could potentially take weeks or months to be discovered; if a prompt injection is inserted externally, or model weights are updated, output drift isn’t always immediately visible. A subtly poisoned AI model looks just like a working one on the surface: both produce outputs. Validation monitoring detects drift, but may not distinguish between natural data drift and adversarial manipulation.

“Frozen” architecture, like version-locked prompts, locked model weights, is partially protective, but only if the locking mechanism itself is secure.

The FDA-EMA Good AI Practice Principles call for multi-disciplinary collaboration for good reason; no single discipline on its own can ensure validated probabilistic outputs. Principle 3 explicitly calls out cybersecurity, and the ISPE GAMP AI Guide (2025) covers adversarial attacks and cybersecurity considerations.

Cybersecurity experts don’t fully understand validation. Validation practitioners don’t fully understand attack vectors. AI engineers are focused on model performance. The gap between these three domains is where the patient safety risk actually lives.

Probabilistic technology has reshaped the landscape of the road, and our guardrails must advance in parallel. The security of the environment is inseparable from the validity of the system.